We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 15,100 | 07:49:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.17 | 85.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/2/2019 15:09 | Gazza you are obsessed about """mechanism for failure""" ... and your lack of understanding is Frightening .. considering you invest in Scancell it relates to SCIB1 .. only why ........ because it has trial results so which has failed .. SCIB1 trial or Keytruda .... Now Bermuda cannot answer that Question Can you ? | inanaco | |
14/2/2019 14:56 | 14 Feb '19 - 11:49 - The REAL LOZAN Motif holders - Am I the only one that thinks Motif might be worth a 'punt' NOW ??? . 75 o/o PROFIT... in 3 hours Perhaps if Flatman took on board the WISDOM of the 'old folks', instead of trying to be 'clever'... but PROVING to *US ALL* he is a 'petulant, underwater trHYPE swallower, cry-baby'...he too could...'GROW UP', and learn how PROFITS are made. . PROFITS are NOT made by being CONned by the BUY,BUY,BUY SCAM CLUB As *US* 'old timers' have PROVED... time and time again. | the real lozan | |
14/2/2019 14:38 | "The reality effect". The reality is I have no aspiration to be some sweaty old git mowing the lawn and having a beer. The effect of realising I'm NOT is really quite wonderful :) | wigwammer | |
14/2/2019 14:34 | wig, who are getting nervous of what? | gazza | |
14/2/2019 14:32 | People seem a bit nervous all of a sudden :) | wigwammer | |
14/2/2019 14:25 | Sorry guys. I thought as Inan could not find a "mechanism of failure" in MTFB when there clearly was in the end, it makes his statement "I can find no mechanism of failure in Scancell" not only meaningless but actually quite stupid. | gazza | |
14/2/2019 14:17 | Yeah... clear off. | tosh123 | |
14/2/2019 13:45 | ONW . The Policeman | inanaco | |
14/2/2019 13:42 | Inanaco So since you're not in MTFB, you don't have the data and this is a BB for Scancell please stop posting on this matter. Perhaps you'd be better going onto the MTFB BB. ATB | oldnotwise | |
14/2/2019 13:36 | Gazza I am not in the share ... or have access to any of the data but when you start questioning the liver function .. they may have seen something to raise concerns """needed to further evaluate the risk for liver toxicity""" | inanaco | |
14/2/2019 13:30 | Inan, >so actually I am at a loss why its been rejected ... i suspect so is MTFB<<br /> Did you fail to find the "mechanism of failure" ? | gazza | |
14/2/2019 13:22 | Berm, i took my medicine the other day and now just try to ignore the plank... please dont encourage the idiot to post here, i dont think anyone is the slightest bit interested in anything that he has to say. The only person remotely interested in his posts, is HIM. | tosh123 | |
14/2/2019 13:22 | That referred to the kidneys .. but it's interesting they have questioned the Liver you would have thought toxicity would be evident in the number treated .. so actually I am at a loss why its been rejected ... i suspect so is MTFB “Iclaprim could potentially solve these issues,” continued Dr. Huang, “Because it is bactericidal and may work among immunocompromised populations, including patients with diabetes, as well as patients with peripheral vascular disease who have micro- and macroangiopathies because it is a small molecule, activity is not affected among patients with gastrointestinal and renal impairment because it is metabolized by CYP 3A4 and 2D19 liver enzymes, does not cause nephrotoxicity and has limited, to no, clinically significant drug-drug interactions that would require dose adjustment of iclaprim. | inanaco | |
14/2/2019 13:07 | Inanaco, can you explain what you mean? 'including the question why did they not run a separate trial for that indication to prove up the claim ..' | bermudashorts | |
14/2/2019 13:06 | Lozan, dont worry, i have no intention of reading anything that the IDIOT has written, its all fairy stories and lies, and utter rubbish. Zero credibility... Zero interest in anything he writes, its all total uneducated nonsense, as we all know.... Even C7 ( his biggest fan )has finally seen the light and has done exactly what was suggested here, and traded his position, NOT " buy and hold " which has cost him so dearly over the last 6 years. The plank just makes himself look silly whenever his fingers touch his keyboard... No interest in the lump of lard what so ever. | tosh123 | |
14/2/2019 12:33 | Tosh i suggest you read my posts on MTFB ...before you band around the word idiot including the question why did they not run a separate trial for that indication to prove up the claim .. | inanaco | |
14/2/2019 11:59 | Lozan, Traders will be all over it until it settles so will all depend on your timing and how well you read the P&D brigade! IMO only of course. | bermudashorts | |
14/2/2019 11:49 | Motif holders - Am I the only one that thinks Motif might be worth a 'punt' NOW ??? | the real lozan | |
14/2/2019 11:12 | Genuinely sorry to hear your news gents, its a bi product of trading on AIM as i know you are more than aware of. Hopefully the follow up meeting with the FDA will pay dividends and provide a means that the reservations shown by the FDA can be put to bed. What this does reinforce as well as hidden / unknown risks, is the importance of mitigating as many risks as possible as soon as possible. Taking advantages of movements in the share price to protect your capital should NOT be seen as weakness, its the exact opposite, its a necessity if you are to make money on any shares, but specifically when dealing in small caps. "Buy and hold" only really applies when dealing in high yielding main index stocks, as the dividends provide an income to help offset any adverse share price movements. The idiot who has been shouting the opposite is exactly that, an IDIOT. I wish you luck with the follow up meeting and hope that everything works out well. | tosh123 | |
14/2/2019 10:50 | Hi Bermuda/ONW Not been a good week st all but win some lose sum and move on. As you say reiterates the fact there is risk in every share transaction and anyone who says otherwise should not be trusted imo You do your best to mitigate that risk by exposure/ research etc but it is always there More platforms here but a lot further away from the market. TC all | ivyspivey | |
14/2/2019 10:44 | Re Motif, Have to admit to having a holding there too, so can't do anything but support Bermuda's 19689. sage comment in my view. ATB | oldnotwise | |
14/2/2019 10:43 | Berm, i was about to post the same as your 19689... you never know where the risks lurk, if you did, you would mitigate them, so just because you cant see them, doesn't mean they dont exist. A sad day, but having just read the RNS, i think that there has been an over reaction and the share price may well recover some of the current losses later in the day. It appears to me that the FDA have not said no, they just want further clarification on the potential renal effects.... but i could be wrong. This looks like it may be one of those instances when a bit of " averaging " may be prudent... maybe. | tosh123 | |
14/2/2019 10:31 | Panama, MTFB were much further down the line applying for marketing approval after 2 successful phase III trials in 600 patients. So a different type of application and different process. | bermudashorts | |
14/2/2019 10:28 | Bermuda, I know nothing of Motif but what timescale has this taken to get a response from the FDA, just trying to compare with the never ending Scancell trial saga. | panama7 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions